{"title":"Specials","description":null,"products":[{"product_id":"retlira-30-30mg-3ml-pen","title":"RETLIRA 30 — 30mg \/ 3ml Research Pen","description":"\u003cp\u003e\u003cstrong\u003eRETLIRA 30\u003c\/strong\u003e is a research-focused peptide product containing \u003cstrong\u003e30mg of R3t@trutide in a 3ml pre-filled pen format\u003c\/strong\u003e, supplied for laboratory and scientific research purposes.\u003c\/p\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eR3t@trutide (LY3437943) is an investigational peptide that has attracted significant scientific interest because of its activity across multiple hormone-receptor pathways, including \u003cstrong\u003eGLP-1, GIP and glucagon receptors\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eRETLIRA 30 provides a clearly identified \u003cstrong\u003e30mg \/ 3ml research format\u003c\/strong\u003e for researchers and laboratories investigating peptide pharmacology and metabolic signalling.\u003c\/p\u003e\n\u003ch3\u003eKey Features\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e30mg R3t@trutide\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e3ml pre-filled research pen format\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eResearch-focused product specification\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIntended for laboratory and scientific research\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eClearly identified concentration and product format\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSuitable for research environments investigating peptide-related pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eResearch Focus\u003c\/h2\u003e\n\u003cp\u003eR3t@trutide is being investigated as a \u003cstrong\u003etriple-receptor agonist\u003c\/strong\u003e, with research examining activity involving GLP-1, GIP and glucagon receptor pathways.\u003c\/p\u003e\n\u003cp\u003eThese pathways are an important area of modern \u003cstrong\u003emetabolic research\u003c\/strong\u003e, with scientists investigating how coordinated receptor signalling may influence glucose regulation, energy metabolism and other physiological processes.\u003c\/p\u003e\n\u003cp\u003eFor additional background, see our article on \u003ca href=\"https:\/\/health-tech.co.za\/blogs\/news\/metabolic-health-explained-the-role-of-glp-1-and-insulin-health-tech\"\u003eGLP-1 and metabolic research\u003c\/a\u003e and our detailed guide to \u003ca href=\"https:\/\/health-tech.co.za\/blogs\/news\/how-triple-agonists-are-changing-obesity-research-the-next-generation-of-metabolic-therapies\"\u003etriple agonist research\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch2\u003eResearch Reference \u0026amp; Study Information\u003c\/h2\u003e\n\u003ch3\u003eR3t@trutide (LY3437943)\u003c\/h3\u003e\n\u003cp\u003eR3t@trutide, also known as \u003cstrong\u003eLY3437943\u003c\/strong\u003e, is an investigational peptide being studied for activity across three hormone-receptor pathways:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGLP-1 receptor\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGIP receptor\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGlucagon receptor\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis multi-receptor activity is the basis for continued investigation into triple agonist approaches within metabolic research.\u003c\/p\u003e\n\u003cp\u003eResearchers interested in comparing receptor approaches can also explore our \u003ca href=\"https:\/\/health-tech.co.za\/blogs\/news\/retatrutide-vs-tirzepatide-whats-the-difference-in-research\"\u003eR3t@trutide vs Tirzepatide research comparison\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch3\u003eKey Research Areas\u003c\/h3\u003e\n\u003cp\u003eResearch involving R3t@trutide includes investigation of:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eMulti-receptor agonism\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGLP-1, GIP and glucagon receptor signalling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eMetabolic pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGlucose regulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEnergy metabolism\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eBody-composition measures\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCardiometabolic research\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSafety and tolerability\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003ePrimary Research Reference\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eJastreboff AM, et al. — Triple–Hormone-Receptor Agonist R3t@trutide for Obesity: A Phase 2 Trial\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eNew England Journal of Medicine\u003c\/em\u003e, 2023;389:514–526.\u003cbr\u003eDOI: \u003cstrong\u003e10.1056\/NEJMoa2301972\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Phase 2 study evaluated LY3437943 in adults with obesity and examined changes in body weight and other clinical outcomes over 48 weeks.\u003c\/p\u003e\n\u003cp\u003eResearchers should consult the original publication when evaluating the study methodology, participant population, endpoints and findings.\u003c\/p\u003e\n\u003ch2\u003eResearch Status\u003c\/h2\u003e\n\u003cp\u003eR3t@trutide remains an \u003cstrong\u003einvestigational compound\u003c\/strong\u003e. RETLIRA 30 is presented by Health-Tech as a research-focused product and is not represented as an approved medicine or treatment.\u003c\/p\u003e\n\u003cp\u003eResearchers should consult peer-reviewed literature, registered clinical-trial records and applicable institutional requirements when evaluating R3t@trutide research.\u003c\/p\u003e\n\u003cp\u003eFor broader scientific background, see \u003ca href=\"https:\/\/health-tech.co.za\/blogs\/news\/peptides-explained-understanding-the-science-research-evidence\"\u003ePeptides Explained: Understanding the Science, Research \u0026amp; Evidence\u003c\/a\u003e.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003eFrequently Asked Questions\u003c\/h1\u003e\n\u003ch3\u003e1. What is RETLIRA 30?\u003c\/h3\u003e\n\u003cp\u003eRETLIRA 30 is a research-focused peptide product containing \u003cstrong\u003e30mg of R3t@trutide in a 3ml pre-filled pen format\u003c\/strong\u003e. It is supplied for laboratory and scientific research purposes.\u003c\/p\u003e\n\u003ch3\u003e2. What is R3t@trutide?\u003c\/h3\u003e\n\u003cp\u003eR3t@trutide is an investigational synthetic peptide also identified in scientific literature as \u003cstrong\u003eLY3437943\u003c\/strong\u003e. Researchers are studying its activity across GLP-1, GIP and glucagon receptor pathways.\u003c\/p\u003e\n\u003ch3\u003e3. What is R3t@trutide being researched for?\u003c\/h3\u003e\n\u003cp\u003eResearch has investigated R3t@trutide in areas including multi-receptor agonism, metabolic signalling, glucose regulation, energy metabolism and broader cardiometabolic research.\u003c\/p\u003e\n\u003ch3\u003e4. How much R3t@trutide is in RETLIRA 30?\u003c\/h3\u003e\n\u003cp\u003eRETLIRA 30 contains \u003cstrong\u003e30mg of R3t@trutide in a 3ml research pen format\u003c\/strong\u003e, according to the product specification.\u003c\/p\u003e\n\u003ch3\u003e5. What is a triple agonist?\u003c\/h3\u003e\n\u003cp\u003eA triple agonist is a compound designed to interact with three receptor pathways. R3t@trutide is being investigated for activity involving the \u003cstrong\u003eGLP-1, GIP and glucagon receptors\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003e6. Why are researchers interested in three receptor pathways?\u003c\/h3\u003e\n\u003cp\u003eMetabolic physiology involves multiple interacting hormonal pathways. Researchers are investigating whether coordinated receptor activity can provide a broader understanding of metabolic regulation.\u003c\/p\u003e\n\u003ch3\u003e7. Is RETLIRA 30 an approved medicine?\u003c\/h3\u003e\n\u003cp\u003eNo. RETLIRA 30 is presented by Health-Tech as a \u003cstrong\u003eresearch-focused product\u003c\/strong\u003e and should not be represented as an approved medicine or treatment.\u003c\/p\u003e\n\u003ch3\u003e8. Where can researchers find information about R3t@trutide?\u003c\/h3\u003e\n\u003cp\u003eResearchers should consult peer-reviewed publications, clinical-trial registries and reputable scientific databases. Health-Tech's educational material is intended as a general research reference and does not replace primary scientific literature.\u003c\/p\u003e\n\u003ch3\u003e9. What is the difference between R3t@trutide and Tirzepatide?\u003c\/h3\u003e\n\u003cp\u003eR3t@trutide is being investigated as a \u003cstrong\u003etriple-receptor agonist involving GLP-1, GIP and glucagon receptors\u003c\/strong\u003e, while Tirzepatide is a dual GIP\/GLP-1 receptor agonist. See our \u003ca href=\"https:\/\/health-tech.co.za\/blogs\/news\/retatrutide-vs-tirzepatide-whats-the-difference-in-research\"\u003eR3t@trutide vs Tirzepatide research comparison\u003c\/a\u003e for further background.\u003c\/p\u003e\n\u003ch3\u003e10. Does Health-Tech provide a human-use protocol for RETLIRA 30?\u003c\/h3\u003e\n\u003cp\u003eNo. Health-Tech does not provide a human-use dosing or administration protocol for this research product. Researchers should follow appropriate institutional procedures, laboratory protocols, safety requirements and applicable regulations.\u003c\/p\u003e\n\u003ch2\u003eResearch Notice\u003c\/h2\u003e\n\u003cp\u003eRETLIRA 30 is presented for \u003cstrong\u003elaboratory and scientific research purposes only\u003c\/strong\u003e. The information provided on this page is educational and research-focused and does not constitute medical advice, treatment guidance or a human-use protocol.\u003c\/p\u003e","brand":"Health-Tech","offers":[{"title":"Default Title","offer_id":48258932998369,"sku":"RETLIRA30","price":2090.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Retlira.png?v=1783589534"},{"product_id":"upret-30mg","title":"UPA Upret 30MG Self-mix Vial + bact water","description":"\u003ch2 data-section-id=\"ae261s\" data-start=\"863\" data-end=\"935\"\u003eUPA Upret 30 MG (R3t@trutide) –Self-Mix - Advanced Triple-Agonist Metabolic Support\u003c\/h2\u003e\n\u003cp data-start=\"937\" data-end=\"1258\"\u003eUpret 30 MG is an advanced R3t@trutide formulation designed to support comprehensive metabolic optimization through its unique triple-receptor mechanism. By targeting GLP-1, GIP, and glucagon pathways simultaneously, R3t@trutide has emerged as one of the most exciting investigational peptides in modern obesity research.\u003c\/p\u003e\n\u003cp data-start=\"1260\" data-end=\"1423\"\u003eR3t@trutide is being studied for its ability to influence appetite regulation, improve satiety, enhance energy expenditure, and support healthy metabolic function.\u003c\/p\u003e\n\u003cp data-start=\"1425\" data-end=\"1585\"\u003eIts multi-pathway approach distinguishes it from first-generation GLP-1 therapies by addressing several mechanisms involved in weight regulation simultaneously.\u003c\/p\u003e","brand":"UPA","offers":[{"title":"Default Title","offer_id":48473879838945,"sku":null,"price":1750.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/2b3ff92e-583e-49a6-bb7f-5350555a7e0a.png?v=1781252257"}],"url":"https:\/\/health-tech.co.za\/collections\/specials.oembed","provider":"Health Tech","version":"1.0","type":"link"}